본문으로 건너뛰기
← 뒤로

Randomized Trial Links Time of Day to Immunotherapy Success.

무작위 임상시험 1/5 보강
Cancer discovery 📖 저널 OA 43.8% 2023: 0/1 OA 2024: 7/8 OA 2025: 14/20 OA 2026: 32/92 OA 2023~2026 2026 Vol.16(3) p. OF1
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
환자: advanced non-small cell lung cancer, in the first randomized trial of immunotherapy timing
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Morning administration of checkpoint inhibitors significantly extended survival in patients with advanced non-small cell lung cancer, in the first randomized trial of immunotherapy timing. The results provide prospective support for aligning treatment with circadian biology as a simple way to improve cancer outcomes.
📝 환자 설명용 한 줄

Morning administration of checkpoint inhibitors significantly extended survival in patients with advanced non-small cell lung cancer, in the first randomized trial of immunotherapy timing.

이 논문을 인용하기

↓ .bib ↓ .ris
APA (2026). Randomized Trial Links Time of Day to Immunotherapy Success.. Cancer discovery, 16(3), OF1. https://doi.org/10.1158/2159-8290.CD-NW2026-0010
MLA . "Randomized Trial Links Time of Day to Immunotherapy Success.." Cancer discovery, vol. 16, no. 3, 2026, pp. OF1.
PMID 41632563 ↗

Abstract

Morning administration of checkpoint inhibitors significantly extended survival in patients with advanced non-small cell lung cancer, in the first randomized trial of immunotherapy timing. The results provide prospective support for aligning treatment with circadian biology as a simple way to improve cancer outcomes.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반